ETON PHARMACEUTICALS INC (ETON)
US29772L1089 - Common Stock
Taking everything into account, ETON scores 4 out of 10 in our fundamental rating. ETON was compared to 194 industry peers in the Pharmaceuticals industry. The financial health of ETON is average, but there are quite some concerns on its profitability. ETON is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
ETON had negative earnings in the past year.
ETON had a positive operating cash flow in the past year.
In the past 5 years ETON always reported negative net income.
The reported operating cash flow has been mixed in the past 5 years: ETON reported negative operating cash flow in multiple years.
1.2 Ratios
ETON has a Return On Assets of -15.29%. This is in the better half of the industry: ETON outperforms 65.63% of its industry peers.
ETON has a Return On Equity of -34.30%. This is in the better half of the industry: ETON outperforms 65.10% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -15.29% | ||
| ROE | -34.3% | ||
| ROIC | N/A |
ROA(3y)-15.37%
ROA(5y)-51.94%
ROE(3y)-28.71%
ROE(5y)-87.68%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
ETON's Gross Margin of 59.30% is fine compared to the rest of the industry. ETON outperforms 66.67% of its industry peers.
The Profit Margin and Operating Margin are not available for ETON so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 59.3% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
ETON does not have a ROIC to compare to the WACC, probably because it is not profitable.
ETON has more shares outstanding than it did 1 year ago.
The number of shares outstanding for ETON has been increased compared to 5 years ago.
The debt/assets ratio for ETON has been reduced compared to a year ago.
2.2 Solvency
An Altman-Z score of 5.02 indicates that ETON is not in any danger for bankruptcy at the moment.
The Altman-Z score of ETON (5.02) is better than 79.17% of its industry peers.
ETON has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 5.02 |
ROIC/WACCN/A
WACC9.1%
2.3 Liquidity
A Current Ratio of 1.51 indicates that ETON should not have too much problems paying its short term obligations.
With a Current ratio value of 1.51, ETON is not doing good in the industry: 75.00% of the companies in the same industry are doing better.
ETON has a Quick Ratio of 1.41. This is a normal value and indicates that ETON is financially healthy and should not expect problems in meeting its short term obligations.
ETON has a Quick ratio of 1.41. This is in the lower half of the industry: ETON underperforms 71.35% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.51 | ||
| Quick Ratio | 1.41 |
3. Growth
3.1 Past
The earnings per share for ETON have decreased strongly by -414.29% in the last year.
ETON shows a small growth in Revenue. In the last year, the Revenue has grown by 5.63%.
ETON shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 824.84% yearly.
EPS 1Y (TTM)-414.29%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%200%
Revenue 1Y (TTM)5.63%
Revenue growth 3Y824.84%
Revenue growth 5YN/A
Sales Q2Q%46.84%
3.2 Future
ETON is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 165.24% yearly.
ETON is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 42.05% yearly.
EPS Next Y-197.5%
EPS Next 2Y231.81%
EPS Next 3Y165.24%
EPS Next 5YN/A
Revenue Next Year15.96%
Revenue Next 2Y45.55%
Revenue Next 3Y42.05%
Revenue Next 5YN/A
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
ETON reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
With a Price/Forward Earnings ratio of 19.89, ETON is valued on the expensive side.
Compared to the rest of the industry, the Price/Forward Earnings ratio of ETON indicates a somewhat cheap valuation: ETON is cheaper than 79.17% of the companies listed in the same industry.
ETON's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 23.82.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 19.89 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
ETON's earnings are expected to grow with 165.24% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y231.81%
EPS Next 3Y165.24%
5. Dividend
5.1 Amount
ETON does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ETON PHARMACEUTICALS INC
NASDAQ:ETON (11/21/2024, 8:25:19 PM)
10.75
+0.32 (+3.07%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap277.78M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 19.89 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -15.29% | ||
| ROE | -34.3% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 59.3% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.97
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.51 | ||
| Quick Ratio | 1.41 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-414.29%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y-197.5%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)5.63%
Revenue growth 3Y824.84%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y